Primary hyperparathyroidism in prostate cancer: guilty or not guilty?

Primary hyperparathyroidism in prostate cancer: guilty or not guilty? Endocrine https://doi.org/10.1007/s12020-018-1632-2 EDITORIAL Primary hyperparathyroidism in prostate cancer: guilty or not guilty? 1 2 3 ● ● G. Mazziotti S. Frara A. Mosca Received: 9 March 2018 / Accepted: 9 May 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Skeletal health is a clinically relevant issue in patients with probability to express PHPT. Notably, PC with the best prostate cancer (PC) [1–3]. Bone is the most common site of prognostic characteristics was considered “protective for PC cell migration with up to 90% of patients with advanced PHPT” by Minisola et al. [9]. disease having bone metastases [4] with potential negative The pathophysiological determinants of these associa- impact on quality of life and survival [5]. Since the first tions were not clarified in this study, but the authors description of the “seed and soil” hypothesis by Stephan hypothesized that in patients with higher PC activity/bio- Paget in 1889 [6], several cellular signaling pathways, logical aggressiveness, as assessed by high GS, osteo- cytokines, chemokines, and adhesion molecules have been blastic bone metastases may favor the development of identified as players of cross-talking between PC cells and PHPT by decreasing serum calcium values [9]. This edi- bone [7] attempting http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Endocrine Springer Journals

Primary hyperparathyroidism in prostate cancer: guilty or not guilty?

Loading next page...
 
/lp/springer_journal/primary-hyperparathyroidism-in-prostate-cancer-guilty-or-not-guilty-DkcvFuRXDq
Publisher
Springer US
Copyright
Copyright © 2018 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Endocrinology; Diabetes; Internal Medicine; Science, Humanities and Social Sciences, multidisciplinary
ISSN
1355-008X
eISSN
1559-0100
D.O.I.
10.1007/s12020-018-1632-2
Publisher site
See Article on Publisher Site

Abstract

Endocrine https://doi.org/10.1007/s12020-018-1632-2 EDITORIAL Primary hyperparathyroidism in prostate cancer: guilty or not guilty? 1 2 3 ● ● G. Mazziotti S. Frara A. Mosca Received: 9 March 2018 / Accepted: 9 May 2018 © Springer Science+Business Media, LLC, part of Springer Nature 2018 Skeletal health is a clinically relevant issue in patients with probability to express PHPT. Notably, PC with the best prostate cancer (PC) [1–3]. Bone is the most common site of prognostic characteristics was considered “protective for PC cell migration with up to 90% of patients with advanced PHPT” by Minisola et al. [9]. disease having bone metastases [4] with potential negative The pathophysiological determinants of these associa- impact on quality of life and survival [5]. Since the first tions were not clarified in this study, but the authors description of the “seed and soil” hypothesis by Stephan hypothesized that in patients with higher PC activity/bio- Paget in 1889 [6], several cellular signaling pathways, logical aggressiveness, as assessed by high GS, osteo- cytokines, chemokines, and adhesion molecules have been blastic bone metastases may favor the development of identified as players of cross-talking between PC cells and PHPT by decreasing serum calcium values [9]. This edi- bone [7] attempting

Journal

EndocrineSpringer Journals

Published: May 30, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off